Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD

NEXT STORY
Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone
PREV STORY
Editas Medicine Announces Second Quarter 2019 Results and Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update

Positive Results from Phase II Trial in CF Program with Number of Potential Strategic ...

author_avatar
NASDAQ Market News

Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5% Following Scandion’s Successful Rights Issue

author_avatar
NASDAQ Market News

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month

author_avatar
NASDAQ Market News